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INTRODUCTION 
Hypertensive disorders of pregnancy complicate 5-10 percent of 
pregnancies and form one among the deadly triad with haemorrhage and 
infection, contributing to maternal morbidity and mortality. According to 
WHO, maternal deaths due to hypertensive disorders in developed 
countries is 16% and haemorrhage is 13%. Pre eclampsia and eclampsia 
account  for about half of these cases worldwide. 
Placental causes of APH contributes to 70% of which 35% is due 
to abruptio placenta. 
Pre eclampsia is still regarded as “a disease of theories”. The 
central pathophysiology in the development of pre eclampsia is 
endothelial dysfunction. 
High levels of homocysteine , or a high “H score” predicts the risk 
of more than 100 diseases and medical conditions. 
Women having higher levels of homocysteine more likely deliver 
prematurely, undergo recurrent abortions and deliver offsprings with low 
birth weight. They also have higher risk of developing pre eclampsia. 
Folic acid supplementation decreases levels of homocysteine during 
pregnancy and reduces CNS malformations. 
                     
2 
 
Homocysteine is a more sensitive marker of vitamin B12, B6 and 
folic acid deficiency and precedes deficiency of circulating vitamins. 
Measurement of total homocysteine levels are now recommended 
to screen for deficiency of vitamins in both high risk and general 
population. 
Several studies have been done to find the association between 
hyperhomocysteinemia and pre eclampsia but only few studies are there 
to know the association between hyperhomocysteinemia, eclampsia and 
abruption. 
           This study is done in a developing country like India at 
Coimbatore medical college hospital to find out the association of 
hyperhomocysteinemia and pre eclampsia , eclampsia and abruption with 
the objective of preventing pre eclampsia,  eclampsia and abruption by 
monitoring Sr. homocysteine as a part of routine antenatal check up.  
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AIMS AND OBJECTIVES 
 
- To study the relationship between the levels of serum 
homocysteine in normal pregnancy and pregnancies complicated 
by pre eclampsia , eclampsia and abruption. 
- To know, if the levels of serum homocysteine are indicators of 
severity of pre eclampsia, eclampsia and abruption, to reduce 
maternofetal morbidity and mortality. 
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REVIEW OF LITERATURE 
Sunita Ghike et al studied serum homocysteine levels during 
normal pregnancy and pre eclampsia and concluded that homocysteine 
levels were reduced in 56% of pregnant normotensive women when 
compared to non pregnant women and levels were increased in 86% of 
women with pre eclampsia. Moreover serum homocysteine levels were 
more in women with severe pre eclampsia when compared to women 
with mild pre eclampsia{1} . This study shows that there is a link between 
increased serum homocysteine levels and pre eclampsia and its severity. 
                Md Mozammel Hoque et al studied serum homocysteine levels 
in pre eclampsia and eclampsia and concluded  that in both pre eclampsia 
and eclampsia the levels of homocysteine were increased 9.54 ± 3.21 
micromoles/litre and 10.57 ±3.39 micromoles/litre respectively{2}. From 
this study we infer that there is a significant increase in homocysteine 
levels in eclampsia in comparison to pre eclampsia. 
Jian Wang et al studied elevated circulating homocysteine levels in 
placental vascular disease and associated pre eclampsia and infered that 
maternal homocysteine levels were increased in pre eclampsia and 
placental umbilical vascular disease but similar change was not seen in 
fetal homocysteine levels with placental vascular disease{3}.This study 
shows that increase in circulating homocysteine levels might be a cause 
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for the pathogenesis of pre eclampsia due to uteroplacental vascular 
disorder. 
Anderson A et al studied the levels of serum homocysteine in 
pregnancy and found that the total levels of serum homocysteine was 
very low in first trimester, it reached maximum in second trimester and 
the levels remained the same till delivery and returned back to normal in 
2-4 days after delivery with P value < 0.05{4}. From this study we infer 
that homocysteine levels are decreased in normal pregnancies. 
Vollset et al studied Plasma total homocysteine, pregnancy 
complications and adverse pregnancy outcomes and found that when 
homocysteine levels increased the risk of pre eclampsia was 32% more, 
for prematurity  it was 38% more and for very low birth weight it was 
101% more. There was significant association between plasma 
homocysteine levels, neural tube defects and club foot. But there was no 
relationship with abruptio placenta and homocysteine levels but when 
total homocysteine levels were >15micromoles/litre there was increased  
risk for abruption{5}. This study suggests a pivotal role of homocysteine 
in indicating pregnancy complications. 
Seema Bibi Qureshi et al studied hyperhomocysteinaemia ,vascular 
related pregnancy complications and response to vitamin supplementation 
in pregnant women of Pakistan and concluded that preterm delivery and 
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low birth weight increased in women with pre eclampsia, eclampsia and  
abruptio placenta with P value < 0.001. Levels of homocysteine were 
considerably increased in pregnancies with pre eclampsia and eclampsia  
when compared to abruptio placenta and normal pregnant women. 
Moreover supplementation of folic acid, vitamin B6 and vitamin B12 
showed a significant decrease in levels of homocysteine in previously 
elevated patients{6}. This study draws our attention to lower homocysteine 
levels by supplementation of folate, vitamin B6 and vitamin B12 in 
pregnant women with hyperhomocysteinemia. 
Theresa O Scholl and William G Johnson studied the influence of 
folic acid on pregnancy outcome and found that deficiency of folate leads 
to hyperhomocysteinemia  which is associated with recurrent abortions, 
pre eclampsia , abruptio placenta , preterm delivery and low birth 
weight{7} . This study insists on folic acid supplementation to prevent 
hyperhomocysteinemia. 
Shilpa A.V. et al studied changes in  homocysteine levels during 
normal pregnancy and pre eclampsia and its relation with oxidative stress 
and concluded that levels of serum homocysteine in pre eclampsia were 
lower compared to non pregnant normal woman with P value 0.001 but 
serum homocysteine levels were higher in pre eclampsia when compared 
to pregnant women without any complications but it was not significant 
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statistically with P value 0.677. This shows that folate intake in first 
trimester in this study might be the cause for minimum increase in 
homocysteine levels compared to pregnant women with no 
complications. The product of lipid peroxidation – malondialdehyde 
levels were measured which showed that in pre eclampsia the levels were 
considerably increased and statistically significant when compared to 
normal non pregnant and pregnant women with P value 0.001{8}. This 
study shows a positive association between homocysteine levels and 
MDA levels in pre eclamptics and infers the role of oxidative stress in its 
pathogenesis. 
Katre P et al studied vitamin B 12 and folic acid supplementation 
and plasma total homocysteine concentrations in pregnant Indian women 
with low B12 and high folate status and concluded that homocysteine 
levels were increased in non supplemented group and the levels were the 
same in women who received only folic acid supplementation. But 
pregnant women who received >1000 micrograms of vitamin B 12 had 
low levels of serum homocysteine{9}. This study conveys the importance 
of supplementation of vitamin  B12 in pregnant women with adequate 
folic acid. 
Noopur Jaiswal et al studied correlation of serum homocysteine 
levels and pregnancy outcome and concluded that levels of serum 
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homocysteine were increased in pregnancy with complications when 
compared to pregnancy without complications but it was statistically not 
significant{10}. Hence this study shows that serum homocysteine levels 
associated with complications of pregnancy and adverse outcome is an 
ongoing trial and whether a particular cut off value of serum 
homocysteine could pre judge the complications of pregnancy is still not 
clear. 
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THEORETICAL BACKGROUND 
HOMOCYSTEINE: 
Homocysteine is a sulphur containing amino acid needed for the 
growth of cells and tissues in the body. It is homologue of cysteine but 
differs by an  added methylene bridge. 
 
It is synthesized from methionine which receives from ATP an 
adenosine group and this reaction is catalyzed by S-Adenosyl methionine 
synthetase and the product is S-Adenosyl methionine. SAM transfers 
methyl group to nor epinephrine / DNA methyl transferase acceptor 
molecule. Then there occurs hydrolysation of adenosine to form L-
homocysteine. Homocysteine so formed is converted back to L-
Methionine via tetrahydrofolate or maybe converted to L-cysteine{11}. 
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 SOURCES OF HOMOCYSTEINE: 
Homocysteine is not obtained from diet but from methionine which 
is found in 
 Dairy products like milk, cheese and yoghurt. 
 Fish and meat. 
 Egg. 
 Vegetables like onions, garlic, broccoli, spinach. 
 Nuts and seeds like sunflower seeds, cashews, sesame seeds 
 and pistachio. 
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Homocysteine levels are regulated by 
 Genetic factor 
 Age 
 Nutritional factors 
 Pregnancy 
The levels of homocysteine are lower in women than in men and 
increases with age{12,13}. This is due to oestrogen lowering effect of 
homocysteine levels{14} in women and increase in homocysteine levels 
with increasing age is due to decreased kidney function{15,16}. 
Homocysteine levels are lower in children more than 1 year of age 
when compared to infants because folate plays an important role in 
children more than one year whereas Vitamin B12 plays a major role as 
primary modulator in infants{17,18}. From 10 years of age, boys have 
elevated homocysteine levels when compared to girls{19}. 
 SERUM HOMOCYSTEINE LEVELS{20-24} 
Non pregnant adult  4.4 to 10.8 micromoles/litre 
First trimester   3.34 to 11 micromoles/litre 
Second trimester   2.0 to 26.9 micromoles/litre 
Third trimester   3.2 to 21.4 micromoles/litre 
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HOMOCYSTEINE  CONCENTRATIONS IN PLASMA 
       Normal           < 10 – 12  micromoles/litre 
       Moderate           12 – 30  micromoles/litre 
        Intermediate      > 30 – 100 micromoles/litre 
         Severe            >100 micromoles/litre 
ETIOLOGY OF  HYPERHOMOCYSTEINEMIA{25} : 
 Vitamin deficiencies : 
                                      Folate 
                                      Vitamin  B 6 ( Pyridoxine ) 
                                      Vitamin  B 12 ( methylcobalamine ) 
 Enzyme defects : 
                                       Methylene tetrahydro folate reductase 
    2 types – C 677 t 
    Thermolabile variant 
                                        Cystathionine beta synthase 
                                        Methionine synthase 
                     Homozygosity is important 
 Drugs 
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ACQUIRED FACTORS THAT INFLUENCE HOMOCYSTEINE 
METABOLISM 
 
FACTOR     HOMOCYSTEINE 
Folate deficiency ↑↑ 
Vitamin B12 deficiency ↑ 
Vitamin B6 deficiency ↑ 
Nitrous oxide ↑ 
Fibrate ↑ 
Niacin ↑ 
Cholestipal colestyramine ↑ 
Methotrexate ↑ 
Trimethoprim ↑ 
Post menopausal hormone 
replacement 
↓ 
Oral contraceptives (↑)? 
Antiepileptics ↑ 
Metformin ↑ 
Omeprazole ↑ 
L-DOPA ↑ 
D-penicillamine ↓ 
                     
14 
 
N-acetylcysteine ↓ 
Tamoxifen ↓ 
Raloxifene ↓ 
Aminoglutethimide ↑ 
Cyclosporine-A ↑ 
Sulfasalazine ↑ 
Isoniazid ↑ 
Psoriasis ↑ 
Acute lymphocytic leukemia ↑ 
Rheumatoid  arthritis ↑ 
Kidney function disorder ↑↑ 
Hypothyroidism ↑ 
Hyperthyroidism ↓ 
Age ↑ 
Post menopause ↑ 
pregnancy ↓ 
Smoking ↑ 
alcohol ↑ 
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PREVALENCE : 
                     Exact prevalence not known. 
                     5-7 % for mild disease 
                      MTHFR mutation 
                                    15 % in European population 
                                    1.4 % in African population 
                                     30% Heterozygous 
                        CBS mutation 
                                     0.4 – 1.4 % Heterozygous 
                                      Rarely Homozygous 
HOMOCYSTEINE & DISEASES 
 
 
 
 
 
 
Homocysteine 
Dementia & 
Alzhemiers 
Disease 
Cardiovascular 
Disease 
Stroke & 
Myocardial 
Infarction 
Osteoporosis 
Diabetes 
Concentration 
and under 
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Pregnancy 
complication 
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HOMOCYSTEINE EFFECT ON CARDIOVASCULAR SYSTEM : 
 
 Arteriosclerotic disease 
 Atherosclerosis by increasing smooth muscle size in 
 blood vessels thereby narrowing the vessel lumen and 
 decreasing the blood supply through reactive oxygen 
 species{26-29}. 
 Deposition of ox LDL and cholesterol in the blood 
 vessels leading to plaque formation and rupture of 
 plaque{30}. 
 Increases clotting mechanism due to its reaction with 
 apolipoprotein and plasma modified fibrin so formed 
 leads to thrombosis{30,31-34}. 
HOMOCYSTEINE EFFECT ON DIABETES : 
 Microangiopathy 
 Macroangiopathy 
 Oxidative stress   leading to atherothrombotic effect. 
 The prognosis is worse for diabetics with homocysteine levels    
>14micromoles/litre{34-37}. 
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 Diabetic retinopathy prevalence is twice high in patients with 
homocysteine levels  > 16 micromoles/litre{37}. 
                  Microalbuminuria , an indicator of glomerular damage 
exponentially increases with increasing levels of homocysteine. 
HOMOCYSTEINE EFFECT ON DEMENTIA, ALZHEIMER’S 
AND COGNITIVE DYSFUNCTION : 
 Increased homocysteine levels leads to decreased  memory 
 and lowers satisfaction in life{38}. 
 Elevated homocysteine levels in elderly people is 
 associated with hippocampal atrophy and atrophy of 
 cortical cerebral regions leading to increase in risk of 
 Alzheimer’s{39}. 
 The risk of Alzheimer’s was increased to 4.5 times in 
 patients with levels of homocysteine ≥ 14 
 micromoles/litre{40}. 
 Nilsson et al showed a link between late onset 
 Alzheimer’s  and homocysteine{41}. 
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HOMOCYSTEINE LEVELS AND CHRONIC KIDNEY 
DISEASE: 
 Homocysteine levels are increased in renal patients,the 
 levels being 20-80 micromoles/litre and this depends on 
 the extent of damage to the kidneys{42,43}. 
 Increased levels of homocysteine is due to defect in 
 remethylation and transsulphuration{44} and also 
 combined with decreased intracellular levels of B12{45}. 
 Vitamin B and N – acetyl cysteine{46} when given in 
 therapeutic dose through intravenous route, decreases or 
 normalizes the levels of plasma homocysteine in patients 
 on dialysis. 
 Few longitudinal studies in patients with renal disease 
 have showed positive association with increased 
 homocysteine levels and mortality rate / increased 
 coronary complications{47}. 
 Other studies showed better prognosis in patients with 
 renal disease with hyperhomocysteinemia{48}, termed 
 “the reverse epidemiology” which denotes homocysteine 
 as a marker of nutritional status. 
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HOMOCYSTEINE LEVELS AND OSTEOPOROSIS: 
 Recent studies have shown a strong link between  increased risk 
 of osteoporotic fracture in older people and moderate elevation of 
 homocysteine levels{49,50}. 
 Goerss et al showed that patients with deficiency of Vitamin B 12 
 leading to pernicious anaemia , have 1.9 fold increased risk of 
 fractures of proximal femur,  1.8 fold increased risk of fractures 
 of vertebra and 2.8 fold  increased risk of fractures of distal 
 forearm compared to controls{51}, thereby showing decreased 
 Vitamin B  levels and hyperhomocysteinemia to increased risk of 
 fractures. 
HOMOCYSTEINE LEVELS AND COMPLICATIONS OF 
PREGNANCY: 
 Normally maternal levels of serum homocysteine decreases as 
gestational age increases. It may be due to physiological pregnancy 
response or maybe due to decreased albumin, increased estrogen, 
hemodilution occurring as a result of  increase in plasma volume and 
increased methionine demand  by mother and foetus. Another proposed 
mechanism is fetal utilization. 
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 Increase in homocysteine levels in pregnant women is 
associated with pre eclampsia , eclampsia , abruption, HELLP syndrome, 
deep vein thrombosis, IUGR, prematurity,LBW,neural tube defects and 
recurrent miscarriages{52}. 
 
 
 
 
 
 
 
 
 
  
Hyperhomocysteinemia 
Preeclampsia 
Placental 
Abruption 
 
preterm labour 
Intra Uterine 
fetal death 
 
IUGR 
Recurrent 
Abortion 
Neural tube 
defects 
 
Spontaneous 
miscarriage 
 
Congenital 
defects 
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TARGET POPULATION IN WHOM SCREENING FOR 
HOMOCYSTEINE IS STRONGLY RECOMMENDED{25} 
Patients with manifested 
vascular 
Diseases 
Coronary heart disease, myocardial infarction, 
atherosclerosis of the carotid artery, peripheral arterial 
occlusive disease, atherosclerosis of the cerebral 
arteries, cerebral insult, venous thrombosis, pulmonary 
arterial embolism 
People at high risk for 
developing 
vascular disease 
Family history, arterial hypertension, smokers, 
hyperlipidaemia, renal insufficiency, diabetes, 
metabolic syndrome, adiposity, factor V-leiden 
mutation 
People at risk for B-
vitamins deficiency 
Older people (> 65 yrs), vegetarians, inflammatory 
bowel diseases, gastritis, malabsorption, tropical sprue, 
chronic diarrhoea, renal diseases, alcohol abuse, 
medications  
People at risk for 
secondary HHCY 
because of their clinical 
situation 
Hypothyroidism, rheumatism, AIDS, complications 
during pregnancy (pre-eclampsia, HELLP syndrome), 
dementia, cognitive decline, Alzheimer disease, 
Parkinson, depression, schizophrenia, osteoporosis 
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SAMPLE COLLECTION: 
 Overnight fasting 
 Morning sample 
 EDTA tube 
 Centrifuged immediately or maybe kept on wet ice till 
 centrifuged. 
METHODS: 
 Chromatography 
 Enzyme Immunoassay ( used routinely ) 
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DEVELOPMENT OF PLACENTA 
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Placenta develops from two sources. Fetal source is the chorion 
frondosum which forms the principal component and maternal source is 
the decidua basalis. 
On the eleventh day after fertilization, interstitial implantation is 
completed and blastocyst is completely surrounded by lacunar spaces 
called trabeculae on all sides. Trophoblast is surrounded by outer 
syncytiotrophoblast and inner cytotrophoblast. Trophoblast further gives 
rise to villous trophoblast and extavillous trophoblast. Stem villi develops 
from trabeculae which later gives rise to primary , secondary and tertiary 
villi. Arterio – capillary- venous system is completed in the mesenchymal 
core of each villus on 21 st day. 
The lacunar spaces filled by maternal blood and lined by syncytial 
cells later becomes intervillous space. 
Decidua capsularis in the abembryonic area lose their villi and 
lacunar spaces and is converted to chorion laeve. 
There occurs enormous subdivision of the villi in the embryonic 
pole and extensive proliferation of decidua basalis forming discrete 
placenta which is completed by 12 th week. 
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Hemochorial development of placenta needs endometrial and spiral 
arterial invasion{53}.This occurs with the help of regulatory factors under 
conditions of hypoxia{54}. 
MMP – 9 plays an important role in trophoblast invasion and this 
in turn is regulated by insulin like growth factor 2 secreted by trophoblast 
which promotes endometrial invasion and this is blocked by insulin like 
growth factor binding protein type 4 secreted by decidual cells. 
  Low levels of estrogen in first trimester of pregnancy is essential 
for remodelling of spiral arteries and invasion of trophoblast. 
Extra villous trophoblast forms interstitial trophoblast and 
endovascular trophoblast. 
The interstitial trophoblast clumps together around spiral arteries 
and also penetrates into the decidua and myometrium and prepares the 
spiral vessels for endovascular invasion of trophoblast{55}. 
Endovascular trophoblasts enter the spiral arteries and forms 
cellular plugs, then by apoptosis damages the vascular endothelium and 
alters the vascular media and causes fibrinoid deposition. Spiral artery 
then regenerates the endothelium. This trophoblastic invasion involves 
only the spiral arteries in decidua basalis and does not involve the 
decidual veins{56}. 
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Thus , this development occurs in two stages.The first stage occurs 
post fertilization upto 12 weeks and involves remodelling of spiral 
arteries upto decidual myometrial border. The second stage occurs in 12 
to 16 weeks , in which there occurs some invasion of spiral arteries in the 
intramyometrium , thereby converting the muscular , small lumen spiral 
arteries into low resistance, high flow and high volume uteroplacental 
circulation{53}. 
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CLASSIFICATION  OF PREGNANCY  INDUCED HYPERTENSION 
National High Blood Pressure Education Programme – 2000  
Updated by ACOG 2013 
Hypertension during pregnancy 
 
 
 
 
 
 
 
 
  
Pregnancy  
induced 
Hypertension 
Chronic 
Hypertension 
 
Chronic 
Hypertension with 
superimposed 
Preeclampsia 
Gestational 
Hypertension 
Preeclampsia Eclampsia 
Mild Preeclampsia Severe Preeclampsia 
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DIAGNOSTIC CRITERIA FOR PREGNANCY ASSOCIATED 
HYPERTENSION( ACOG 2013 ) 
Gestational  Hypertension 
Blood pressure > 140 / 90 mm Hg in previously normotensive    women 
after 20 weeks of gestation.     
Pre eclampsia 
 Hypertension and 
Proteinuria                 > or = 300 mg / 24 hours 
Protein creatinine ratio > or = 0.3 
Dipstick 1 + persistant 
Or 
 Thrombocytopenia      platelets < 1 lakh / microlitre 
Renal insufficiency     creatinine  > 1.1 mg / dl or doubling  of 
baseline.         
Liver involvement       serum transaminase levels twice Normal.       
Cerebral symptoms      Headache ,visual disturbances ,  Convulsions.   
 Pulmonary edema          
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Pre eclampsia : 
It is a pregnancy specific syndrome of unknown etiology and is 
characterized  by development of hypertension  > or = 140/90 mm Hg 
with proteinuria after 20 weeks of gestation  involving multiple systems 
in previous normotensive and non proteinuric women.                                                                                    
 Eclampsia : 
Convulsions in women who also meets the criteria for pre  eclampsia. 
 Associated neurological disease ruled out. 
Chronic Hypertension : 
 Hypertension developing  < 20 weeks of gestational age .
 Hypertension persistent beyond 12 weeks postpartum. 
Superimposed  pre eclampsia : 
 Development of pre eclampsia in women with chronic hypertension 
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INDICATORS OF SEVERITY OF HYPERTENSIVE 
DISORDERS{57} : 
 NON SEVERE SEVERE 
Systolic  BP < 160 mm Hg >or = 160 mm Hg 
Diastolic BP < 110 MM Hg >or = 110 mm Hg 
Proteinuria  None to positive >5 g in 24 hours 
Oliguria Absent <400 ml / 24 hours 
Headache Absent Present 
Visual disturbances Absent Present 
Persistent epigastric pain Absent Present 
Thrombocytopenia Absent Present   < 1 lakh     
Serum transaminase levels Minimal elevation Marked elevation 
Serum creatinine Normal Elevated 
Pulmonary edema Absent Present 
IUGR Absent Present 
Convulsion Absent Present 
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INCIDENCE : 
           Incidence in nullipara is 3-10 %{58} 
Genetic predisposition , race ,  ethnicity, socio economic and seasonal 
changes influence the incidence of pregnancy induced hypertension{59}. 
            Incidence of pre eclampsia in singleton pregnancy – 5 %. 
            Incidence of pre eclampsia in twin pregnancy – 13 %.{60} 
RISK FACTORS  : 
 Primi gravida 
 Multifetal gestation 
 Molar pregnancy 
 Diabetes complicating pregnancy 
 Obesity 
 Family history of hypertension 
 Pre existing vascular disease 
 New paternity 
 Thrombophilias 
 Women with pre eclampsia in previous pregnancy are at 
greater risk for developing pre eclampsia in second pregnancy{62}. 
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Kraus et al mentioned that smoking upregulates placental adrenomedullin 
expression which upregulates volume homeostasis and decreases risk of 
hypertension during pregnancy{61} 
ETIOPATHOGENESIS : 
 Exposed  to chorionic villi for the first time 
 Inflammation or endothelial cell activation 
 Genetic predisposition 
 Exposure to abundant chorionic villi as in molar pregnancy and 
 multifetal gestation. 
               “2 stage disorder”  theory as proposed by NESS AND 
ROBERTS includes “maternal and placental pre eclampsia”. 
REDMAN & CO WORKERS proposed that 
Stage 1   Faulty remodelling of endovascular trophoblasts. 
Stage 2  Clinical syndrome. 
Stage 2 is modified by maternal conditions by endothelial cell activation 
or inflammation. 
                     
33 
 
 
 
                     
34 
 
ETIOLOGY : 
 ABNORMAL TROPHOBLAST INVASION 
 
 Trophoblastic invasion is incomplete in which                                                                                
endovascular trophoblast line the decidual arteries but not   the                                                        
myometrial arterioles{63}. 
 Decreased soluble anti angiogenic growth factors. Endothelial cell 
damage ,myointimal cell proliferation and medial necrosis.  
Vascular lesions leading to narrowing of spiral arterioles ,atherosis 
and infarcts. 
 IMMUNOLOGICAL FACTORS : 
                MHC antigens are absent in villous trophoblasts but MHC 
Class 1 is expressed on invasive extra villous trophoblasts. 
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 HLA G plays an important role by preventing immune rejection of 
extravillous trophoblasts by modulating the functions of uterine natural 
killer cells{64}. 
 There occurs abnormal HLA G expression in pre eclampsia in extra 
villous trophoblasts{65}. 
                   Dysregulation of maternal immunological tolerance to fetal 
antigens and paternal derived placental antigens is another proposed 
mechanism in pre eclampsia{66}. 
 ENDOTHELIAL CELL ACTIVATION 
 Endothelial injury caused by TNF- alpha and interleukins may  
lead to oxidative stress due to free radicals  leading to self propagating 
formation of  lipid peroxides{67} thereby modifying production of nitric 
oxide and causing  prostaglandin  imbalance. 
 NUTRITIONAL FACTORS: 
             -  Diet rich in fruits and vegetables having antioxidant activity 
  lowers blood pressure. 
 - Trials showed that antioxidant vitamins like vitamin C or E 
  supplementation did not show any added benefits. 
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 GENETIC  FACTORS: 
GENE FUNCTION AFFECTED 
MTHFR(C6771) Methylene tetrahydrofolate 
reductase 
F5(Leiden) Factor V 
AGT(M235T) Angiotensinogen 
HLA Human leukocyte antigen 
NOS3(Glu 298 Asp) Endothelial nitric oxide 
F2(G20210A) Prothrombin 
ACE Angiotensin converting enzyme 
CTLA4 Cytotoxic T- lymphocyte 
associated protein 
SERPINE 1 Serine peptidase inhibitor 
 
FUNCTIONS  OF  NORMAL  ENDOTHELIUM : 
 Two major functions of intact endothelium   
 -coagulation prevention 
 -vascular tone modulation 
Central role in PIH is endothelial injury. 
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Features of  PIH are preceeded by endothelial dysfunction. 
 
PATHOGENESIS: 
 VASOSPASM 
  - vasoconstriction as a result of endothelial activation. 
- Damage to endothelial cells leading to interstitial leakage of 
 platelets and fibrinogen. 
- subendothelial deposition leading to diminished blood flow. 
- intense attenuation of blood volume in severe pre eclampsia{68}. 
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 ENDOTHELIAL CELL INJURY 
- circulating endothelial cell levels in peripheral blood is 
 increased{69}. 
- increased sensitivity to vasopressors. 
- endothelial cell damage promotes substances leading to 
 coagulation{70}. 
- increased endothelial microparticles in circulation{71}. 
 - decrease in prostacyclin and thromboxane A2 ratio. 
 - increase in nitric oxide inactivation due to decreased expression of 
 endothelial nitric oxide synthase{72}. 
- increase in endothelin 1 which is a potent vasoconstrictor. 
PATHOPHYSIOLOGY 
 CARDIOVASCULAR SYSTEM 
- increase in cardiac after load due to hypertension. 
- decrease in hypervolemia of pregnancy leading to decreased 
 cardiac preload. 
- endothelial activation with extravasation to the extracellular 
 spaces. 
- increase in peripheral vascular resistance leads to decrease in 
 cardiac output{73}. 
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 HEMATOLOGICAL CHANGES: 
- decrease in blood volume expansion to the extent of 16% which is 
 about 50% in normal pregnant women{74}. 
- marked hemo concentration 
- endothelial injury leading to microangiopathic hemolysis. 
- Thrombocytopenia 
- increase in fibronectin 
 HORMONAL CHANGES 
- increased sensitivity to vascular pressor agents like angiotensin 2, 
 cathecolamines and vasopressin  leading to increase in vascular 
 resistance. 
- alteration in prostacyclin and thromboxane A2 ratio.  
- Increase in levels of pro atrial natriuretic peptide. 
 KIDNEY 
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- renal blood flow and glomerular filtration rate are increased in 
normal pregnancy. 
- decrease in renal  perfusion and glomerular filtration occurs in pre 
eclampsia. 
- decrease in glomerular filtration rate is due to increased resistance 
of renal afferent arterioles. 
Microscopic Features 
- glomerular capillary endotheliosis. 
- deposition of proteins and fibrin like material subendothelially. 
Increase in sr. creatinine  levels due to decreased GFR. 
Increase in plasma uric acid is due to increased tubular reabsorption. 
  LIVER 
- Characteristic feature is periportal haemorrhage in the periphery of 
 liver. 
-  Haematoma in subcapsular region. 
- haemorrhage and rupture of glisson’s capsule leading to life 
 threatening intraperitoneal bleed. 
- elevation in levels of serum hepatic transaminases. 
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-  In HELLP syndrome there occurs, hemolysis, elevated liver 
 enzymes and low platelet counts. 
 BRAIN 
- cerebral blood flow and cerebral oxygen metabolism is normal in 
 pre eclampsia{75}. 
 - Increase in cerebral vascular resistance occurs in pre eclampsia. 
- Subcortical edema, softening of brain and haemorrhage in white 
 matter occurs. 
- Parieto occipital cortex is most frequently affected. 
-  cerebro vascular hyperperfusion manifests as headache and 
 scotomata. 
- Eclampsia occurs due to release of glutamate excessively which is 
 a excitatory neurotransmitter, bursts of action potential and massive 
 depolarization of neurons. 
- On MR imaging- hyperintense T2 leisons in subcortical and 
 cortical areas of parieto occipital lobes. 
- Basal ganglia, brainstem and cerebellum are also involved. 
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  RETINA 
GRADING OF HYPERTENSIVE RETINOPATHY 
GRADE 1:    Slight to moderate narrowing of retinal vessels with 
    A: V ratio>1:2 
GRADE 2:  Moderate to severe narrowing of retinal arteries with 
 arterio: Venous ratio<1:2 
GRADE 3:  Soft exudates and flame shaped haemorrhages. 
GRADE 4:  Grade 3 changes and bilateral optic nerve edema. 
Blindness is rare and is reversible and it is due to 
- occipital lobe involvement – amaurosis, 
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- Retinal involvement – serous retinal detachment / infection called 
 as purtscher retinopathy. 
 
 EFFECT ON FETUS 
- uteroplacental insufficiency 
- intrauterine  growth restriction 
- Oligohydraminos. 
- Preterm labour 
- increased risk of abruption. 
PREDICTIVE TESTS FOR PRE ECLAMPSIA 
 Placental Perfusion/Vascular Resistance 
 Roll over test 
 Isometric handgrip test 
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 Pressor response to aerobic exercise 
 Mid trimester mean arterial pressure 
 Angiotensin II infusion 
 Uterine artery or fetal transcranial Doppler velocimetry 
  Fetal Placental Unit 
 Human chorionic gonadotrophin 
 Alpha feto protein 
 Pregnancy associated protein A 
 Estriol 
 Inhibin A 
 Activin A 
 Placental protein 13 
 CRH 
 ADAM Metallopeptidase domain 12 
 Kisspeptin 
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  Renal Dysfunction 
 Serum uric acid 
 Micro Albuminuria 
 Urinary calcium/kallikrein 
 N Acetyl beta glucosaminidase 
 Micro transferrinuria 
 Cystatin C 
 Podocyturia 
  Endothelial Dysfunction 
 Platelet count and activation 
 Fibronectin 
 Endothelial adhesion molecules 
 C reactive protein 
 Homocysteine 
 Angiogenic factors 
 Fms – like tyrosine kinase receptor -1 
 Endoglin 
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 Others 
 Antithrombin III 
 Atrial natriuretic peptide 
 Beta II microglobulin 
 Genetic markers 
 Cell free fetal DNA 
 Serum and urine proteomics 
 Metabolomic markers 
 25 hydroxy vitamin D 
HYPERHOMOCYSTEINEMIA IN PRE ECLAMPSIA 
        - Causes endothelial damage. 
        - Thromboembolic effects 
        - Placental hypoperfusion. 
        - Excess production of toxic free radicals 
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ECLAMPSIA 
Preeclampsia complicated with generalized tonic-clonic convulsions 
/coma.  
seizures ,most commonly occurs in third trimester. 
Seizures can occur 
  ANTE PARTUM 
It constitutes upto 50% of cases. 
Seizures occur most often before start of labour and labour ensues 
soon after. 
 INTRAPARTUM 
It constitutes upto  30% of cases. 
  POSTPARTUM 
 Contributes upto  20% 
seizures occurring for first time within 48-72 hours after delivery. 
 LATE POSTPARTUM 
Seizures occurring beyond 48  hours of child birth but less than 4 
weeks. 
STAGES 
 PREMONITORY STAGE 
- lasts for 30 seconds. 
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- patient becomes unconscious. 
- muscles of face, tongue and limbs undergo twitching 
- Eyeballs roll and become fixed. 
 TONIC STAGE 
- Lasts for 30 seconds. 
- tonic spasm of the body occurs 
- tongue protrudes 
- Respiration stops. 
- cyanosis appears 
- eyeballs fixed 
 CLONIC STAGE 
- Lasts for 1-4 minutes. 
- Alternate contraction and relaxation 
- Breathing becomes stertorous. 
- cyanosis disappears. 
 STAGE OF COMA 
CAUSE 
- Anoxia 
- cerebral edema 
- cerebral dysrhythmia 
                     
49 
 
ABRUPTIO PLACENTA 
It is the premature separation of normally situated placenta. 
VARIETIES 
   - Revealed 
   - Concealed 
   - Mixed 
Bleeding is mostly maternal rarely fetal as in traumatic abruption . 
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INCIDENCE: 
      Occurs in 1 in 200 deliveries. 
      Perinatal mortality   15-20% 
      Maternal mortality  2-5% 
ETIOLOGY 
 DEMOGRAPHIC FACTORS 
- Higher birth order: 
3 times more common in Gravida 5 and above (Pritchard 1991) 
Torhey 1993 
- Advancing maternal age 
Women > 40 years have 2-3 times increased risk of abruption when 
compared to women ≤35years.( Cleary Goldman ,2005 ) 
- Race or ethinicity 
- Familial association 
Women having severe abruption , the risk of abruption was 
doubled in her sister and heritability risk was 16%{80}. (Rasmussen, 
2009). 
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 HYPERTENSION AND PRE ECLAMPSIA 
Zetterstrom and  associates found increased incidence of 
abruption in chronic hypertensives compared to normotensive 
women{78,79}. Pre eclampsia  superimposed on chronic hypertension  
confers greater risk of abruption. 
 TRAUMA 
 PRETERM PREMATURE RUPTURE OF MEMBRANES 
 CIGARETTE SMOKING 
 COCAINE ABUSE 
 THROMBOPHILIAS AND LUPUS ANTICOAGULANT 
 UTERINE LEIOMYOMAS 
 RECURRENT ABRUPTION 
In case of previous mild abruption recurrent risk is 6.5 fold increased and 
with severe abruption recurrent risk is 11.5 fold increasesd. 
Women with history of two severe abruptions, the risk is increased 50 
fold. 
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PATHOGENESIS 
      - Impaired invasion of trophoblasts with atherosis is seen in some 
 cases of pre eclampsia and abruption{76} (Brosens, 2011) 
      - Infection /Inflammation as proposed by Nath and Collegues{77}. 
      - Bleeding into the deciduas basalis 
      - Decidual hematoma forms 
CHANGES IN ORGANS 
 COUVELAIRE UTERUS 
Also known as uteroplacental apoplexy. 
Naked eye – uterus is port wine colour which is patchy or diffuse 
Subperitoneal haemorrhages 
Necrosis of the affected area 
Infiltration of blood and fluid between muscle bundles. 
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 ACUTE KIDNEY INJURY 
 CONSUMPTIVE COAGULOPATHY 
 SHEEHAN SYNDROME 
CLINICAL CLASSIFICATION DESCRIBED BY PAGE 
GRADE 0 –  Clinical features absent.  
Diagnosis made only on  placental inspection 
GRADE I –   Vaginal bleeding is minimal.  
Uterus irritable and tenderness absent.                      
   No Signs of maternal shock or fetal distress.           
GRADE II – Vaginal bleeding is mild to moderate 
                       Uterine tenderness present 
                        No signs of maternal shock 
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                         Fetal distress/ fetal death present 
GRADE III –  Bleeding moderate to severe / concealed.  
uterine tenderness marked. 
  Shock present 
  Fetal death 
  Coagulation disorder/ anuria may be present 
CLINICAL FEATURES OF REVEALED AND MIXED VARIETY 
     PARAMETERS        REVEALED          MIXED 
Symptoms 
 
Abdominal pain followed 
by bleeding per vaginum 
Intense acute abdominal 
pain followed by slight 
vaginal bleeding 
Character of bleeding Slight to moderate, 
continuous dark colour 
Slight , continous dark 
colour 
General condition Proportionate to visible 
blood loss 
Shock is pronounced 
Pallor Related to visible blood 
loss 
Severe , out of proportion 
to visible blood loss 
Features of Pre 
eclampsia 
May be present Frequent association 
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Uterine height Proportionate to 
gestational age 
May be disproportionately 
enlarged 
Uterine feel Normal with localized 
tenderness, contractions 
frequent 
Uterus is tense , tender 
and rigid 
Fetal parts Can be made out easily Not made out easily 
Fetal heart sound Usually present Usually absent 
Urine output Normal Usually decreased 
Lab tests   
Haemoglobin Low , proportionate to 
blood loss 
Markedly lower, out of 
proportion to visible 
blood loss 
Coagulation profile Normal Clotting time increased 
  Platelet count low 
Fibrinogen level low 
Increased APTT 
Increased FDP and D-
dimer 
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MATERIALS AND METHODS 
 
Study design    -  prospective study 
Study place     -  Department of obstetrics and gynecology,  
    Coimbatore medical college hospital             
Study duration     - Oct 2016 to Sep  2017 
Inclusion criteria: 
 Booked antenatal women 21-35 years of age 
 Gestational age 34-40 weeks 
Exclusion Criteria 
 Diabetes mellitus 
 Essential Hypertension 
 Recurrent pregnancy loss 
 Liver disease 
 Multiple pregnancies 
 Severe Anaemia 
 Smoking and tobacoo chewers 
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 Pregnancy with APLA syndrome 
 Polyhydraminos 
 Thyroid disorders 
Group I   
          Sample size of 40 normotensive healthy pregnant women fullfilling 
the inclusion criteria. 
Group II 
Sample size of 40 pregnant women in inclusion criteria with BP ≥ 
140/90mm Hg with proteinuria > 2+ in dipstick in random urine sample. 
Group III 
          Sample size of 40 pregnant women satisfying the inclusion criteria 
with onset of generalized tonic clonic seizures /coma superimposed on 
pre eclampsia. 
Group IV 
            Sample size of 40 pregnant women with abruption included in 
inclusion criteria with clinical and USG diagnosis. 
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During the period of  Oct 2016 to Sep 2017, patients coming to Obstetrics 
and gynaecology department in Coimbatore medical college hospital with 
above criteria are grouped. 
A detailed history including patient’s age race, parity, 
socioeconomic status menstrual, medical history, obstetric, past, dietary 
and treatment history noted. 
General examination, systems and obstetric examinations done. 
Routine investigations like blood grouping, haemoglobin, urine albumin 
sugar, HIV, HbsAg, Blood Sugar, VDRL and Ultra Sound are done. 
Women in group II, III and IV - special investigations of blood urea, 
serum creatinine, platelet count, Serum lactate dehydrogenase, Bleeding 
time,Clotting time, liver enzymes, sr. uric acid were done. Serum 
homocysteine levels were done in all patients. 5ml of venous blood drawn 
from antecubital vein and sent in labelled bottles to lab immediately and 
centrifuged within 3000 rpm for 5 mins . Serum separated is analysed by 
chemilumniscent microparticle immuno assay and values were recorded.
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OBSERVATION AND RESULTS 
     The following pages are the tables and graphs which gives us the 
descriptive analysis of 160 patients in the study according to age, parity, 
gestational age, prepregnancy BMI, previous  history, risk factors, 
investigations, maternal and fetal complications, birth weight and  serum 
homocysteine levels. 
 
 
TABLE -1 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE 
 
 
 
 
 
 
    In this study 118 (73.8%) patients belong to age group 21 to 30 years 
and 42 patients  (26.2%) belong to age group 31 to 35 years. 
 
 
 
Age Frequency Percent 
21-30 yrs 118 73.8 
31-35 yrs 42 26.2 
Total 160 100.0 
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TABLE-2 
 
DISTRIBUTION OF PATIENTS ACCORDING TO PARITY 
 
    
 78 Patients in this study are primigravida, 61 patients are 2nd gravida and 
21 patients are 3rd  gravida or more. 
 
 
Parity Frequency Percent 
First  pregnancy 78 48.8 
Second  pregnancy 61 38.1 
Third pregnancy or more 21 13.1 
Total 160 100.0 
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TABLE-3 
DISTRIBUTION OF PATIENTS ACCORDING TO 
GESTATIONAL AGE 
 
 
    67 Patients in this study are in 34 to 36 weeks of gestation and 93 
patients are in 37 to  40 weeks of gestation. 
 
 
 
 
 
Gestational Age Frequency Percent 
34 - 36 weeks 67 41.9 
37 - 40 weeks 93 58.1 
Total 160 100.0 
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TABLE-4 
 
DISTRIBUTION OF PATIENTS ACCORDING TO                                 
PRE PREGNANCY BMI 
 
 
 
 
 
 
 
 
   Increase in prepregnancy BMI has an increased risk of developing 
PIH, which was proved from many studies, hence this factor is included 
in this study. 7.5% of patients in this study  have BMI more than 30 and 
92.5% have BMI less than 30. 
 
 
 
 
BMI Frequency Percent 
>30 12 7.5 
<30 148 92.5 
Total 160 100.0 
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TABLE-5 
DISTRIBUTION OF PATIENTS ACCORDING TO PREVIOUS 
HISTORY 
 
14 patients have previous history of pre eclampsia, 1 patient has history 
of eclampsia and 6   have past history of abruption. 
 
 
 
Previous History Frequency Percent 
Preeclampsia 14 8.8 
Eclampsia 1 .6 
Abruption 6 3.8 
No 61 38.1 
Not applicable 78 48.8 
Total 160 100.0 
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TABLE-6 
 
DISTRIBUTION OF PATIENTS ACCORDING TO RISK FACTOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study 21 patients have mild pre eclampsia, 19 patients have severe 
pre eclampsia, 40  patients have eclampsia and 40 patients have 
abruption. 
 
Risk Factor Frequency Percent 
Mild Preeclampsia 21 13.1 
Severe Preeclampsia 19 11.9 
Eclampsia 40 25.0 
Abruption 40 25.0 
No risk factor/ Normal 
pregnancy 
40 25.0 
Total 160 100.0 
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TABLE-7 
 
DISTRIBUTION OF PATIENTS ACCORDING TO 
INVESTIGATIONS 
 
 
 
 
 
 
 
 
 
 
 
In this study investigations were abnormal in 85 patients and were normal 
in 75 patients. 
 
 
 
Investigations Frequency Percent 
Abnormal 85 53.1 
Normal 75 46.9 
Total 160 100.0 
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TABLE-8 
DISTRIBUTION OF PATIENTS ACCORDING TO MATERNAL 
COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No complications occured in 122 patients. 13 patients developed CVT, 11 
patients developed  renal failure and maternal death occurred in one. 
 
Maternal complications 
 
Frequency Percent 
Renal failure 11 6.9 
HELLP 6 3.8 
CVT 13 8.1 
DIVC 2 1.2 
Pulmonary complications 2 1.2 
Shock 1 .6 
PPH 1 .6 
Sepsis 1 .6 
Maternal Death 1 .6 
No complications 122 76.2 
Total 160 100.0 
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TABLE-9 
DISTRIBUTION OF BABIES ACCORDING TO BIRTH WEIGHT 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study, 82 babies weighed more than 2.5 kg, 60 babies weighed 
between 2 to 2.5 kg and   18 babies weighed less than 2 kg. 
 
 
Birth  
Weight 
Frequency Percent 
>2.5 - 3.5 82 51.2 
2 - 2.5 60 37.5 
<2 18 11.2 
Total 160 100.0 
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TABLE-10 
DISTRIBUTION OF BABIES ACCORDING TO FETAL 
COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
In this study 77 babies are normal, 52 babies are pre term, 23 are IUGR 
and  fetal death  occurred  in 8.  
Fetal                 
complications 
Frequency Percent 
Preterm 52 32.5 
IUGR 23 14.4 
Fetal death 8 5.0 
No 77 48.1 
Total 160 100.0 
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TABLE 11 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE AND RISK 
FACTOR 
 
* Significant at 5% level of significance 
** Significant at 1% level of significance 
 
 
 
 
 
 
 
 
Risk Factor 
Total P value 
Mild 
Preeclampsia 
Severe 
Preeclampsia Eclampsia Abruption 
No risk 
 factor/  
Normal 
pregnancy 
Age 
21-30 
yrs 
No 15 17 31 15 40 118 
0.000** 
% 71.4% 89.5% 77.5% 37.5% 100.0% 73.8% 
31-35 
yrs 
No 6 2 9 25 0 42 
% 28.6% 10.5% 22.5% 62.5% .0% 26.2% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-1 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE AND RISK 
FACTOR 
 
 
 
From the above table and graph, it is seen that mild pre eclampsia is seen 
in 71.4%, severe pre  eclampsia in 89.5% and eclampsia is seen in 77.5% 
of patients in 21 to 30 years of age. Abruption is seen in 62.5% patients in 
31 to 35 years of age with p value at 1% level of significance. 
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TABLE-12 
DISTRIBUTION OF PATIENTS ACCORDING TO PARITY AND RISK 
FACTOR 
 
 
  
   Risk Factor 
Total P value 
   Mild Preeclampsia Severe Preeclampsia Eclampsia Abruption 
No risk factor/ 
Normal pregnancy 
Parity 
First  pregnancy 
No 17 13 30 10 8 78 
0.000** 
% 81.0% 68.4% 75.0% 25.0% 20.0% 48.8% 
Second  pregnancy 
No 4 6 8 15 28 61 
% 19.0% 31.6% 20.0% 37.5% 70.0% 38.1% 
Third pregnancy or 
more 
No 0 0 2 15 4 21 
% .0% .0% 5.0% 37.5% 10.0% 13.1% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-2 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE AND RISK 
FACTOR 
 
 
 
From the above table and graph 81% of mild pre eclampsia, 68.4% of 
severe pre eclampsia and   75% of eclampsia is seen in primigravida.70% 
of abruption is seen in 2nd gravida and more  with P value at 1% level of 
significance. 
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TABLE-13 
 
DISTRIBUTION OF PATIENTS ACCORDING TO GESTATIONAL 
AGE IN    WEEKS AND RISK FACTOR 
 
 
 
 
 
 
 
   Risk Factor 
Total 
P value 
   Mild 
Preeclamp
sia 
Severe 
Preeclamp
sia 
Eclamps
ia 
Abrupti
on 
No risk 
factor/ 
Normal 
pregnancy 
GA In 
weeks 34 - 36 
weeks 
No 9 14 9 29 6 67 
0.000** 
% 42.9% 73.7% 22.5% 72.5% 15.0% 41.9% 
37 - 40 
weeks 
No 12 5 31 11 34 93 
% 57.1% 26.3% 77.5% 27.5% 85.0% 58.1% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-3 
DISTRIBUTION OF PATIENTS ACCORDING TO GESTATIONAL 
AGE IN WEEKS AND RISK FACTOR 
 
 
 
x-axis → number of patients. 
y-axis→ gestational age in weeks. 
p value at 1% level of significance.  
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TABLE-14 
DISTRIBUTION OF PATIENTS ACCORDING TO PRE 
PREGNANCY BMI AND RISK FACTOR 
 
 
  
   Risk Factor 
Total P value 
   
Mild 
Preeclamp
sia 
Severe 
Preeclamp
sia 
Eclamps
ia 
Abrupti
on 
No risk 
factor / 
Normal 
pregnancy 
Pre 
pregnanc
y BMI 
>30 
No 0 4 5 0 3 12 
0.022* 
% .0% 21.1% 12.5% .0% 7.5% 7.5% 
<30 
No 21 15 35 40 37 148 
% 100.0% 78.9% 87.5% 100.0% 92.5% 92.5% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-4 
DISTRIBUTION OF PATIENTS ACCORDING TO PRE 
PREGNANCY BMI AND RISK FACTOR 
 
 
x-axis→ BMI 
y-axis→ number of patients 
p value at 5% level of significance  
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TABLE-15 
DISTRIBUTION OF PATIENTS ACCORDING TO PREVIOUS 
HISTORY AND RISK FACTOR 
 
 
   Risk Factor 
Total P Value 
   
Mild 
Preecla
mpsia 
Severe 
Preeclamp
sia 
Eclam 
psia 
Abrup 
tion 
No risk  
factor/ 
 Normal  
pregnancy 
Previous 
History 
Preecla
mpsia 
No 3 2 4 2 3 14 
0.000 
% 21.4% 14.3% 28.6% 14.3% 21.4% 100.0% 
Eclamps
ia 
No 0 0 1 0 0 1 
% .0% .0% 100.0% .0% .0% 100.0% 
Abruptio
n 
No 0 1 0 5 0 6 
% .0% 16.7% .0% 83.3% .0% 100.0% 
No 
No 1 3 5 24 28 61 
% 1.6% 4.9% 8.2% 39.3% 45.9% 100.0% 
Not 
applicab
le 
No 17 13 30 9 9 78 
% 21.8% 16.7% 38.5% 11.5% 11.5% 100.0% 
Total 
No 21 19 40 40 40 160 
% 13.1% 11.9% 25.0% 25.0% 25.0% 100.0% 
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GRAPH- 5 
DISTRIBUTION OF PATIENTS ACCORDING TO PREVIOUS 
HISTORY AND RISK FACTOR 
 
 
 
 
In this study 35.7% of pre eclamptics had past history of pre eclampsia, 100% 
of patients with past   history of eclampsia developed eclampsia and 83.3% of 
patients developed abruption with p value at  1% level of significance. 
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TABLE-16 
DISTRIBUTION OF PATIENTS ACCORDING TO 
INVESTIGATIONS AND RISK FACTOR 
 
 
 
 
 
 
 
   Risk Factor 
Total 
P  
value 
   
Mild Pre 
eclampsia 
Severe 
Pre 
eclampsia 
Eclampsia Abruption 
No risk 
factor/ 
Normal 
pregnancy 
Invest 
igations 
Abnormal 
No 0 18 37 30 0 85 
0.000** 
% .0% 94.7% 92.5% 75.0% .0% 53.1% 
Normal 
No 21 1 3 10 40 75 
% 100.0% 5.3% 7.5% 25.0% 100.0% 46.9% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-6 
DISTRIBUTION OF PATIENTS ACCORDING TO 
INVESTIGATIONS AND RISK FACTOR 
 
 
 
 
x-axis→number of patients 
y-axis→investigations 
p value at 1% level of significance  
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TABLE-17 
DISTRIBUTION OF PATIENTS ACCORDING TO BIRTH  
WEIGHT AND RISK FACTOR 
 
  
   Risk Factor 
Total 
P value 
   
Mild 
Preeclampsi
a 
Severe 
Preeclampsi
a 
Eclampsi
a 
Abruptio
n 
No risk 
factor/ 
Normal 
pregnancy 
Birth 
Weight 
>2.5 - 3.5 No 
18 0 13 11 40 82 
0.000** 
%  85.7% .0% 32.5% 27.5% 100.0% 51.2% 
2 - 2.5 No 3 6 22 29 0 60 
%  14.3% 31.6% 55.0% 72.5% .0% 37.5% 
<2 No 0 13 5 0 0 18 
%  .0% 68.4% 12.5% .0% .0% 11.2% 
Total No 
21 19 40 40 40 160 
%  
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH 7 
DISTRIBUTION OF PATIENTS ACCORDING TO BIRTH  
WEIGHT AND RISK FACTOR 
 
 
 
 
 
x-axis→ number of patients 
y-axis→ birth weight of babies 
p value at 1% level of significance.  
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TABLE-18 
 
DISTRIBUTION OF PATIENTS ACCORDING TO FETAL 
COMPLICATIONS AND RISK FACTOR 
  
   Risk Factor 
Total P value 
   Mild Preeclampsia 
Severe 
Preeclamp
sia 
Eclamps
ia 
Abrupti
on 
No risk 
factor/ 
Normal 
pregnancy 
Fetal 
complications 
Preterm 
No 1 8 10 33 0 52 
0.000** 
% 4.8% 42.1% 25.0% 82.5% .0% 32.5% 
IUGR 
No 1 10 12 0 0 23 
% 4.8% 52.6% 30.0% .0% .0% 14.4% 
Fetal 
death 
No 0 1 1 6 0 8 
% .0% 5.3% 2.5% 15.0% .0% 5.0% 
No 
No 19 0 17 1 40 77 
% 90.5% .0% 42.5% 2.5% 100.0% 48.1% 
Total 
No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-8 
DISTRIBUTION OF PATIENTS ACCORDING TO FETAL 
COMPLICATIONS AND RISK FACTOR 
 
 
 
In this study, 90.5 % of babies born to mild pre eclamptics are normal. 
52.6% of babies born to  severe pre eclamptics and 30% born to 
eclamptics have IUGR and 82.5% babies born to  patients with abruption 
are preterm with p value at 1% level of significance.  
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TABLE-19 
DISTRIBUTION OF PATIENTS ACCORDING TO MATERNAL COMPLICATIONS AND RISK FACTOR 
  
   Risk Factor 
Total 
P value 
   Mild Preeclampsia Severe Preeclampsia Eclampsia Abruption No risk factor/ 
Normal pregnancy Maternal 
complications 
Renal failure No 0 2 3 6 0 11 0.000** 
% .0% 10.5% 7.5% 15.0% .0% 6.9% 
HELLP No 0 4 2 0 0 6 
% .0% 21.1% 5.0% .0% .0% 3.8% 
CVT No 0 5 8 0 0 13 
% .0% 26.3% 20.0% .0% .0% 8.1% 
DIVC No 0 0 0 2 0 2 
% .0% .0% .0% 5.0% .0% 1.2% 
Pulmonary 
complications 
No 0 0 2 0 0 2 
% .0% .0% 5.0% .0% .0% 1.2% 
                     
86 
 
 
 Shock No 0 0 0 1 0 1  
% .0% .0% .0% 2.5% .0% .6% 
PPH No 0 0 0 1 0 1 
% .0% .0% .0% 2.5% .0% .6% 
Sepsis No 0 0 0 1 0 1 
% .0% .0% .0% 2.5% .0% .6% 
Maternal 
Death 
No 0 0 0 1 0 1 
% .0% .0% .0% 2.5% .0% .6% 
No 
complications 
No 21 8 25 28 40 122 
% 100.0% 42.1% 62.5% 70.0% 100.0% 76.2% 
Total No 21 19 40 40 40 160 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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GRAPH-9 
DISTRIBUTION OF PATIENTS ACCORDING TO MATERNAL 
COMPLICATIONS AND RISK FACTOR 
 
 
 
In this study mild pre eclamptics did not develop any complications. CVT 
is seen in 26.3% of  severe pre eclamptics and 20% of eclamptics. 
HELLP syndrome is seen in 21.1% of severe pre eclamptics. Renal 
failure developed in 15% of patients with abruption and 10.5% of patients  
with severe pre eclampsia. DIVC is seen in 5% of patients with abruption 
and maternal death occurred in 2.5% of abruptions. 
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TABLE-20 
 
DISTRIBUTION OF PATIENTS ACCORDING TO SERUM 
HOMOCYSTEINE LEVELS AND RISK FACTOR 
 
 
 
 
 
 
 
 
Risk Factor Mean N Std. Deviation 
P value 
Mild Preeclampsia 12.9467 21 1.45837 0.000** 
Severe 
Preeclampsia 16.2779 19 .52248 
Eclampsia 18.7338 40 1.61880 
Abruption 6.9795 40 .71221 
No risk factor/ 
Normal pregnancy 5.9467 40 .41856 
Total 11.5472 160 5.49306 
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GRAPH-10 
DISTRIBUTION OF PATIENTS ACCORDING TO SERUM 
HOMOCYSTEINE LEVELS AND RISK FACTOR 
 
 
 
X-axis→ risk factor 
Y-axis→ mean value of serum homocysteine levels 
P value at 1% level of significance.  
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TABLE-21 
 
DISTRIBUTION OF PATIENTS ACCORDING TO SERUM 
HOMOCYSTEINE LEVELS AND MATERNAL                                    
COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maternal complications Mean N 
Std. 
Deviation 
P value 
Renal failure 11.8982 11 6.10805 0.000** 
HELLP 17.5033 6 2.06152 
CVT 18.9585 13 2.19650 
DIVC 8.5350 2 .07778 
Pulmonary 
complications 
20.1750 2 2.62337 
Shock 6.9500 1 . 
PPH 6.7500 1 . 
Sepsis 7.0500 1 . 
Maternal Death 8.9500 1 . 
No complications 10.4761 122 5.00589 
Total 11.5472 160 5.49306 
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GRAPH-11 
DISTRIBUTION OF PATIENTS ACCORDING TO SERUM 
HOMOCYSTEINE LEVELS AND MATERNAL                                    
COMPLICATIONS 
 
 
 
X-axis→maternal complications 
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                                                             DISCUSSION 
                  Importance of serum homocysteine levels has been described 
in 1960s by Dr.Kilmer McCully. Increased homocysteine levels is a risk 
factor for endothelial dysfunction and vascular disease. 
                  In pregnant woman, increased homocysteine level is likely to 
injure the vascular endothelium. Vascular changes caused by 
homocysteine are similar to that seen in preeclampsia and eclampsia. 
                  The association between increased levels of homocysteine and 
preeclampsia has been suggested by Dekker et al(81). The relationship has 
been shown in early pregnancy by Cotter et al(82),2nd trimester by 
Sorensen et al(83) and 3rd trimester by Sanchez et al(84). 
                  In our study maximum number of patients belong to 20-30 
years of age(73.8%).In the study done by Mozammel Hoque et al,all 
patients were in 20-30 years of age and in  study done by Qureshi et al 
majority of patients belonged to 20-30 years of age. 
                  In our study, 48.8% of patients are primigravida and all 
patients belong to 34-40 weeks of gestation. In study done by Qureshi et 
al 32 -40 weeks of gestational age was included. 
                  In our study, the severity of preeclampsia is directly related to 
hyper homocysteinemia with mean homocysteine levels being 12.94 
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micro mol/L in mild preeclampsia,16.2 micro mol/L in severe 
preeclampsia and 5.94 micro mol/L in normal pregnancies with p value 
being 0.000 ,similar to  study of Khosrowbeygi et al85 where the 
homocystiene levels are 11.49 +/- 1.19 micro mol/L in mild preeclampsia 
, 17.4+/- 2.7 micro mol /L in  severe preeclampsia and 6.38 +/- 0.3 micro 
mol /L in normal pregnancies with p value 0.000. 
                  In our study homocysteine levels are increased in pre 
eclampsia and eclampsia but levels in eclampsia are higher (18.7 micro 
mol/L) than in severe preeclampsia( 16.2 micro mol/L) similar to  
Mozammel Hoque et al where levels in eclampsia are 10.57 +/- 3.39 
micro mol /L and in pre eclampsia it is 9.54 +/-  3.21 micro mol /L. 
                  Our study does not show an association between 
homocysteine levels and placental abruption similar to  studies of Qureshi 
et al and Steegeres et al(52). 
                   Our study shows an association between increased 
homocysteine levels and low birth weight with p value being 0.000 
similar to  studies of Qureshi et al and Murphy et al(86) with p value being 
less than 0.001. 
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 Mozammel Hoque et 
al 
Qureshi et al Our study 
Age 20-30 yrs 22-32 yrs 20-35 yrs 
Gestational  
age 
26-34 weeks 32-40 weeks 34-40 weeks 
 Patient 
count 
Serum 
 Homocyste-
ine 
 levels 
(Micromoles  
per litre) 
Patient 
count 
Serum  
Homocyste-
ine 
 levels 
(Micromoles 
 per litre) 
Patient  
count 
Serum  
Homo-
cysteine 
 levels 
(Mi-
cromoles 
 per litre) 
 
Normal 
pregnancy 
Preeclamsia 
Eclampsia 
Abruption 
 
136 
 
84 
120 
 
6.86±2.47 
 
9.54±3.21 
10.57±3.39 
112 
 
61 
49 
110 
8.19±3.05 
 
9.42±3.91 
10.07±7.71 
7.83±4.65 
 
40 
 
80 
40 
40 
5.94 
 
16.20 
18.70 
6.97 
 
P value 0.000 0.01 0.000 
 
  From the above study , it is seen that measuring homocysteine levels 
during pregnancy will help us to predict the development of 
preeclampsia,eclampsia and abruption. 
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SUMMARY 
 
               A study is made on 160 antenatal patients who attended the 
obstetrics and gynaecology department in Coimbatore medical college to 
know the levels of serum homocysteine in preeclampsia, eclampsia , 
abruption and normal pregnancies and whether the levels were indicators 
of severity over a period of one year. 
 In our study, preeclampsia and eclampsia is common in 
 primigravida. 
 62.5 % of abruptions occured  with advancing age of mother and  
 more common in second gravida or more. 
 Mild pre eclamptics did not develop any complications. CVT is 
 more commonly seen in severe preeclampsia (26.3%) and 
 eclampsia (20%). 
 Growth restriction of fetuses is more common with severe 
 preeclampsia  (52.6%) and preterm babies is common with 
 abruption (82.5%) 
 Serum homocysteine levels are indicators of severity in pre 
 eclampsia and eclampsia but there was no association with 
 abruption with p value at 1% level of significance. 
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 Our study involves small population and hence association 
 between Serum homocysteine and abruptio placenta is not proved. 
 Studies have supported the evidence of lowering Serum 
 homocysteine levels by supplementing vitamin B and folic acid. 
 Hence supplementation of folic acid and B complex vitamins from 
 first trimester of pregnancy can be useful in reducing serum 
 homocysteine  levels thereby preventing preeclampsia, eclampsia, 
 abruption and its complications which is yet to be proved by 
 further studies. 
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CONCLUSION 
 Measurement of serum homocysteine levels can be included in 
routine ante natal care management in the hospital. 
 Severity of the disease can be interpreted by the levels of 
homocysteine. 
 Homocysteine levels can be lowered by supplementation with folic 
acid and other B complex vitamins as supported by studies in 
review of literature, there by preventing maternal and fetal 
complications. 
 Based on these studies, in a low resource setting and developing 
country like India, to be cost effective, B complex vitamins along 
with peri conceptional folic acid supplementation from early 
pregnancy can be very useful to prevent hyperhomocysteinemia   
and related diseases like preeclampsia , eclampsia and abruption 
and its complications there by reducing maternofetal morbidity and 
mortality.  
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                                                          ANNEXURE 1 
                                                           PROFORMA 
 
Name :                                        Age :                                         IP NO : 
Address : 
Parity :  
LMP :                             EDD :  
Chief complaints :  
Menstrual history : 
Marital history : 
Obstetric history : 
            History of pre eclampsia,eclampsia and abruption in previous pregnancy 
is asked for. 
Past history : 
            Associated  risk  factors 
Family history : 
Personal history : 
            Dietary history  
            Treatment taken 
Examination of patient : 
 General condition : 
Anaemia/pedal edema/clubbing/lymphadenopathy/nutritional status 
114 
 
 
Pulse rate : 
Blood pressure : 
CVS : 
RS : 
Per abdomen : 
Per vaginal : 
Investigations : 
   Blood grouping & typing 
   Haemoglobin 
   Platelet count 
   Urine albumin 
              Sugar 
    HIV 
   HbsAg 
   VDRL 
   Blood sugar 
 
Special investigations 
Blood urea  
Serum creatinine 
LFT 
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Bleeding time 
Clotting time 
PT,aPTT 
Serum uric acid 
Serum homocysteine levels 
Ultrasound 
CT brain if needed 
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ANNEXURE -2 
CONSENT FORM 
Yourself Mr./Mrs./Ms………………………………..  are being asked to be a 
participant in the research study titled " A COMPARATIVE ANALYSIS OF 
SERUM HOMOCYSTEINE LEVELS IN PRE ECLAMPSIA, 
ECLAMPSIA, ABRUPTIO PLACENTA AND NORMAL 
PREGNANCIES" in CMC Hospital, Coimbatore, conducted by                         
DR. V.K.T ANNURADHA, Post Graduate Student, Department of 
OBSTETRICS AND GYNAECOLOGY, Coimbatore Medical College. You 
are eligible after looking into the inclusion criteria. You can ask any question 
you may have before agreeing to participate. 
Purpose of Research 
-  To study the relationship between the levels of serum homocysteine in 
normal pregnancy and pregnancies complicated by pre eclampsia , 
eclampsia and abruption. 
- To know, if the levels of serum homocysteine are indicators of severity of 
pre eclampsia, eclampsia and abruption, to reduce maternofetal morbidity 
and mortality. 
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Decline from Participation 
 You have the option to decline from participation in the study existing 
protocol for your condition. 
Privacy and Confidentiality 
 Privacy of individuals will be respected and any information about you or 
provided by you during the study will be kept strictly confidential. 
Authorization to publish Results   
 Results of the study may be published for scientific purposes and/or 
presented to scientific groups, however you will not be identified.               
Statement of Consent 
 I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to me, and 
I may ask questions at any time. 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(volunteer)   
--------------------------------                          ------------------------------
Signature of witness                                               Date 
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xg;g[jy; gotk;  
 
bgah;  - 
ghypdk; - 
taJ  -  
Kfthp - 
muR nfhit kUj;Jtf;fy;Y}hpapy; kfg;ngW kUj;Jt Jiwapy; gl;l 
nkw;gog;g[ gapYk; khztp mDuhjh tp.nf.o mth;fs; nkw;bfhs;Sk;         
nQhnkhrp!;od; vd;Dk; g[ujj;jpd; jd;ikia kfg;ngW fhyj;jpy; 
,uj;jj;jpy; mstpl;L nkYk; mjdhy; vw;gLk; gpd;tpist[fis gw;wpa[k; 
Ma;tpy; bra;Kiw kw;Wk; midj;J tptu';fisa[k; nfl;L bfhz;L 
vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; fye;J 
bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; 
,e;j Ma;tpypUe;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;.  
,g;gof;F 
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KEY TO MASTER CHART 
Age :                
21-30 yrs            -             1 
31-35 yrs             -            2 
Parity :           
First pregnancy   -           1 
                    Second pregnancy   -      2 
Third pregnancy        -      3 
Or more 
GA in weeks :  
    34-36 weeks        -          1 
                         37-40 weeks       -          2 
Pre pregnancy BMI : 
      >30           -         1 
                                     <30           -          2 
Previous h/o : 
preeclampsia        -          1 
Eclampsia           -          2 
Abruption            -          3 
No risk factors              -          4 
Not applicable               -          5 
 
Risk factors :  
Mild preeclampsia      -          1 
Severe preeclampsia      -          2 
Eclampsia           -          3 
Abruption          -          4 
120 
 
Normal pregnancy   -          5 
Investigations : 
Abnormal        -          1 
Normal            -          2 
Maternal complications : 
Renal failure         -          1 
HELLP              -         2 
CVT                -         3 
DIVC               -         4 
Pulmonary complication           -         5 
Shock              -         6 
PPH                  -         7 
Sepsis              -          8 
Maternal death             -         9 
No complications            -          10 
 
Birth weight : 
2.5 kg – 3.5 kg             -         1 
2.0kg -  2.5 kg              -         2 
< 2.0 kg               -          3 
 
Fetal complications : 
Preterm                   -          1 
IUGR                      -            2 
Fetal death                  -          3 
Congenital malformations     -          4 
No complications         -           5 
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MASTER CHART 
 
S.No I.P No Age Parity GA In weeks 
Prepregnancy 
BMI 
Previous 
History 
Risk 
Factor Investigations 
Serum 
Homocysteine 
Levels 
Maternal 
complications 
Birth 
Weight 
Fetal 
complications 
1 259256 1 2 2 2 4 5 2 6.19 10 1 5 
2 319258 1 2 2 2 4 5 2 6.25 10 1 5 
3 281963 1 2 2 2 4 5 2 6.03 10 1 5 
4 963825 1 1 2 2 5 5 2 5.18 10 1 5 
5 754632 1 1 2 2 5 5 2 5.75 10 1 5 
6 842425 1 1 2 2 5 5 2 5.26 10 1 5 
7 132854 1 1 2 2 5 5 2 5.13 10 1 5 
8 263859 1 1 2 2 5 5 2 6.08 10 1 5 
9 748563 1 2 2 2 4 5 2 5.9 10 1 5 
10 825714 1 2 2 2 4 5 2 5.81 10 1 5 
11 109574 1 2 2 2 4 5 2 5.67 10 1 5 
12 857496 1 2 2 2 4 5 2 6.42 10 1 5 
13 235689 1 2 2 2 4 5 2 6.1 10 1 5 
14 135287 1 2 2 2 4 5 2 6.32 10 1 5 
15 745698 1 2 2 2 4 5 2 6.03 10 1 5 
16 896475 1 2 2 2 4 5 2 5.62 10 1 5 
17 365869 1 2 2 2 4 5 2 5.89 10 1 5 
18 724965 1 2 2 2 4 5 2 5.54 10 1 5 
19 123765 1 2 2 2 4 5 2 5.38 10 1 5 
20 845936 1 2 2 2 4 5 2 5.04 10 1 5 
21 759462 1 2 2 2 4 5 2 6.18 10 1 5 
22 798465 1 2 2 2 4 5 2 6.22 10 1 5 
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23 253625 1 2 2 2 4 5 2 6.98 10 1 5 
24 402635 1 2 2 2 4 5 2 6.52 10 1 5 
25 256398 1 3 2 2 1 5 2 6.48 10 1 5 
26 865945 1 3 1 2 1 5 2 6.33 10 1 5 
27 125874 1 2 1 2 1 5 2 6.27 10 1 5 
28 746369 1 2 1 2 4 5 2 5.99 10 1 5 
29 124658 1 2 1 2 4 5 2 5.87 10 1 5 
30 123458 1 1 2 1 5 5 2 5.65 10 1 5 
31 875846 1 1 1 1 5 5 2 6.24 10 1 5 
32 457865 1 1 2 1 5 5 2 6.01 10 1 5 
33 235985 1 3 1 2 4 5 2 5.93 10 1 5 
34 956582 1 3 2 2 4 5 2 6.14 10 1 5 
35 457865 1 2 2 2 4 5 2 6.25 10 1 5 
36 978758 1 1 1 2 5 1 2 11.01 10 1 5 
37 484444 1 1 1 2 5 1 2 11.96 10 1 5 
38 936784 1 1 1 2 5 1 2 12.02 10 1 5 
39 123854 1 1 1 2 5 1 2 12.26 10 1 5 
40 963748 1 1 1 2 5 1 2 11.99 10 2 1 
41 741852 1 1 1 2 5 1 2 12.04 10 1 5 
42 963825 1 1 1 2 5 1 2 13.05 10 1 5 
43 662513 1 1 1 2 5 1 2 13.48 10 1 5 
44 885596 1 1 1 2 5 1 2 13.56 10 1 5 
45 768254 1 1 2 2 5 1 2 13.64 10 1 5 
46 142578 2 1 2 2 5 1 2 13.41 10 1 5 
47 325566 2 1 2 2 5 1 2 12.98 10 1 5 
48 123450 2 1 2 2 5 1 2 12.54 10 1 5 
49 321856 1 2 2 2 1 1 2 12.67 10 1 5 
50 404044 1 1 2 2 5 1 2 13.12 10 1 5 
51 213854 2 1 2 2 5 1 2 13.44 10 1 5 
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52 525657 2 1 2 2 5 1 2 13.65 10 1 5 
53 504058 2 1 2 2 5 1 2 14.05 10 2 2 
54 779856 2 1 1 1 5 2 1 15.06 10 3 1 
55 701548 1 1 1 1 5 2 1 15.98 2 3 2 
56 632109 2 1 1 1 5 2 1 15.91 10 3 2 
57 418529 1 1 1 1 5 2 2 15.97 10 3 2 
58 101891 1 1 1 2 5 2 1 16.04 3 3 1 
59 907525 1 1 1 2 5 2 1 16.22 10 3 1 
60 785629 1 1 1 2 5 2 1 16.85 3 3 1 
61 801852 1 1 1 2 5 2 1 16.49 10 3 2 
62 665425 1 1 1 2 5 2 1 16.84 2 3 3 
63 415028 1 1 1 2 5 2 1 16.87 1 3 1 
64 102856 1 1 1 2 5 2 1 15.97 10 3 1 
65 449286 1 1 1 2 5 2 1 16.54 3 3 1 
66 854769 1 1 2 2 5 2 1 15.55 10 2 2 
67 754863 1 2 2 2 1 2 1 17.01 3 2 2 
68 824225 1 2 1 2 1 2 1 16.54 1 3 1 
69 708465 1 2 2 2 4 2 1 16.96 3 2 2 
70 614253 1 2 2 2 4 2 1 16.53 10 2 2 
71 348569 1 1 2 2 5 3 1 20.02 3 2 2 
72 475685 1 1 2 2 5 3 1 17.01 10 1 5 
73 602514 1 1 2 2 5 3 1 18.91 3 1 5 
74 512865 1 1 2 2 5 3 1 17.89 3 1 5 
75 321301 1 1 2 2 5 3 1 17.77 10 1 5 
76 623019 1 1 2 2 5 3 1 17.99 1 1 5 
77 552657 1 1 2 2 5 3 1 16.52 10 1 5 
78 440444 1 1 2 2 5 3 1 17.03 10 1 5 
79 895956 1 1 2 2 5 3 1 15.92 10 1 5 
80 594565 1 1 2 2 5 3 1 18.06 10 1 5 
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81 857486 1 1 2 2 5 3 1 16.7 10 1 5 
82 501807 1 1 2 2 5 3 1 19.33 1 1 3 
83 732185 1 1 2 2 5 3 1 18.32 5 2 2 
84 882898 2 1 2 2 5 3 1 17.41 10 2 2 
85 613425 2 1 2 2 5 3 1 16.91 10 2 2 
86 141415 2 1 2 2 5 3 1 17.99 10 2 2 
87 701526 2 1 2 2 5 3 1 16.99 10 2 2 
88 825936 2 1 2 2 5 3 1 20.31 2 1 5 
89 789456 2 1 2 2 5 3 1 19.94 2 2 2 
90 795546 2 1 2 2 5 3 1 17.96 10 2 5 
91 844225 2 1 2 2 5 3 1 18.02 10 2 5 
92 827514 1 1 2 2 5 3 1 18 10 2 5 
93 764396 1 1 2 2 5 3 1 17.96 10 2 5 
94 676582 2 1 2 2 5 3 1 17.89 10 2 5 
95 501256 1 1 2 2 5 3 1 18.05 10 2 5 
96 765095 1 2 2 2 1 3 1 19.06 10 2 1 
97 623109 1 2 2 2 2 3 1 19.33 10 2 2 
98 448324 1 2 2 2 1 3 1 18.64 10 1 2 
99 741852 1 2 2 2 1 3 1 17.59 10 2 2 
100 552658 1 2 2 2 4 3 1 18 10 2 2 
101 500165 1 2 1 1 4 3 1 20.22 1 3 1 
102 701508 1 2 1 1 4 3 1 21.34 3 3 1 
103 805092 1 2 1 1 4 3 1 21.14 3 3 1 
104 916852 1 3 1 2 1 3 1 20.26 3 3 1 
105 874856 1 3 1 2 4 3 1 19.45 10 3 1 
106 970255 2 2 1 2 4 4 2 7.52 10 2 1 
107 789224 2 2 1 2 4 4 2 7.99 10 2 1 
108 932784 2 2 1 2 4 4 2 7.25 10 2 1 
109 741802 2 2 1 2 4 4 2 7.39 10 2 1 
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110 875486 2 2 1 2 4 4 2 6.18 10 2 1 
111 412348 2 2 1 2 4 4 2 6.23 10 2 1 
112 950011 2 2 1 2 4 4 2 6.95 10 2 1 
113 801218 2 2 1 2 4 4 1 6.49 10 2 1 
114 770154 2 2 1 2 4 4 1 6.28 10 2 1 
115 791072 2 2 1 2 4 4 1 7.01 10 2 1 
116 838659 2 2 1 2 4 4 1 7.55 10 2 1 
117 876895 2 3 1 2 4 4 1 8.48 4 2 3 
118 928659 2 3 1 2 4 4 1 8.59 4 2 3 
119 707514 2 3 1 2 4 4 1 8.95 9 2 3 
120 842684 2 3 1 2 4 4 1 7.51 10 2 3 
121 751751 2 3 1 2 4 4 1 6.82 10 2 3 
122 845865 2 3 1 2 4 4 1 6.75 10 2 3 
123 897867 2 3 2 2 4 4 1 6.72 10 1 1 
124 854847 2 3 2 2 4 4 1 6.35 10 1 1 
125 799999 2 3 2 2 4 4 1 6.92 10 1 1 
126 821614 2 3 2 2 4 4 1 7.89 10 1 1 
127 948964 2 3 2 2 4 4 1 7.26 10 1 1 
128 886688 2 3 2 2 4 4 1 6.22 10 1 1 
129 893865 2 3 2 2 3 4 1 6.45 1 1 1 
130 901542 2 1 2 2 4 4 1 6.56 1 1 1 
131 912865 1 1 2 2 5 4 1 6.12 10 1 1 
132 955873 1 1 1 2 5 4 1 6.17 10 1 1 
133 937542 1 1 1 2 5 4 1 6.65 1 1 1 
134 960459 1 1 1 2 5 4 1 6.89 1 2 1 
135 922523 1 2 1 2 1 4 1 6.95 6 2 1 
136 964825 1 2 1 2 1 4 1 6.75 7 2 1 
137 994201 1 2 1 2 3 4 1 7.36 10 2 1 
138 896523 1 2 1 2 3 4 1 6.27 10 2 1 
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139 878658 1 3 1 2 3 4 1 6.25 10 2 1 
140 831259 1 3 1 2 3 4 1 7.05 8 2 1 
141 257489 1 2 2 2 4 5 2 6.12 10 1 5 
142 384569 1 2 2 2 4 5 2 6.18 10 1 5 
143 687412 1 2 2 2 4 5 2 5.98 10 1 5 
144 695412 1 2 2 2 4 5 2 5.29 10 1 5 
145 787573 1 2 2 2 4 5 2 5.65 10 1 5 
146 848280 1 2 2 2 1 1 2 9.23 10 1 5 
147 664259 1 2 2 2 1 1 2 15.96 10 1 5 
148 489426 1 2 2 2 4 1 2 15.82 10 2 5 
149 284596 1 2 2 2 4 2 1 15.94 2 2 2 
150 747673 1 2 1 2 3 2 1 16.01 2 2 2 
151 778498 1 1 1 2 5 3 1 18.33 10 2 1 
152 845896 1 1 1 1 5 3 1 20.94 3 2 1 
153 321456 1 1 1 1 5 3 2 22.03 5 2 1 
154 654123 1 1 1 2 5 3 2 22.56 3 2 1 
155 258369 1 1 2 2 5 3 2 21.56 10 2 2 
156 963852 1 1 1 2 5 4 2 6.12 10 2 1 
157 654321 1 1 1 2 5 4 2 6.4 1 2 1 
158 558488 1 1 1 2 5 4 2 6.98 1 2 1 
159 947151 1 1 2 2 5 4 1 7.14 10 2 1 
160 677485 1 1 2 2 5 4 1 7.77 10 2 5 
 
